logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Salix Pharmaceuticals, Inc. drugs

    FiltersReset Filters
    4 results

    • moviprep

      (POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE)
      Salix Pharmaceuticals, Inc.
      Usage: MoviPrep® is an osmotic laxative indicated for colonic cleansing prior to colonoscopy in adults.

    • relistor

      (Methylnaltrexone bromide)
      Salix Pharmaceuticals, Inc.
      Usage: RELISTOR is indicated for treating opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced illness requiring opioid escalation for palliative care, including those with chronic pain related to prior cancer or its treatment.

    • uceris

      (budesonide)
      Salix Pharmaceuticals, Inc.
      Usage: UCERIS rectal foam is indicated for inducing remission in patients with active mild to moderate distal ulcerative colitis, specifically when it extends up to 40 cm from the anal verge.

    • xifaxan

      (rifaximin)
      Salix Pharmaceuticals, Inc.
      Usage: XIFAXAN is indicated for treating travelers’ diarrhea caused by noninvasive E. coli in patients aged 12 and older, reducing hepatic encephalopathy recurrence in adults, and managing irritable bowel syndrome with diarrhea in adults. It should only be used for infections due to susceptible bacteria to prevent resistance.